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a b s t r a c t
Loss of physiological microglial function may increase the propagation of neurodegenerative diseases.
Cellular senescence is a hallmark of aging; thus, we hypothesized age could be a cause of dystrophic
microglia. Stereological counts were performed for total microglia, 2 microglia morphologies (hyper-
trophic and dystrophic) across the human lifespan. An age-associated increase in the number of
dystrophic microglia was found in the hippocampus and frontal cortex. However, the increase in
dystrophic microglia was proportional to the age-related increase in the total number of microglia. Thus,
aging alone does not explain the presence of dystrophic microglia. We next tested if dystrophic microglia
could be a disease-associated microglia morphology. Compared with controls, the number of dystrophic
microglia was greater in cases with either Alzheimer's disease, dementia with Lewy bodies, or limbic-
predominant age-related TDP-43 encephalopathy. These results demonstrate that microglia dystrophy,
and not hypertrophic microglia, are the disease-associated microglia morphology. Finally, we found
strong evidence for iron homeostasis changes in dystrophic microglia, providing a possible molecular
mechanism driving the degeneration of microglia in neurodegenerative disease.
 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Inflammation and cellular senescence are hallmarks of aging
(Kennedy et al., 2014; Lopez-Otin et al., 2013). Almost 2 decades
ago, dystrophic microglia were described with beading and frag-
mentation of the branches of the microglia (Streit et al., 2004).
While the cellular processes appear to be fragmented, they are
actually intact, with the bead-like portions connected by thin
(0.18 mm) channels (Tischer et al., 2016). In contrast to the hyper-
trophic microglia often seen following CNS injury, the dystrophic
microglia were proposed to be a form of microglia senescence
(Streit et al., 2004).
While there is no single specific marker of cellular senescence, a
handful of markers, such as p16INK4a, and p21WAF1/Cip1, have some
affinity for identifying senescent cells (Gorgoulis et al., 2019). Using
a p16INK4a approach to target the removal of senescent cells in a
mouse model of tauopathy resulted in reduced tau pathology,
neuronal degeneration, and cognitive deficits (Bussian et al., 2018).
Given the necessary cellular stressors, microglia can become se-
nescent/dystrophic, as recently reported after a TBI in aged mice,
where an increase in the senescent markers p16INK4a and p21WAF1/
Cip1 were seen in microglia (Ritzel et al., 2019).
Throughout the body, cellular senescence is associated with the
secretion of inflammatory mediators, defined as the senescence-
associated secretory phenotype. The senescence-associated secre-
tory phenotype includes the production of matrix metal-
loproteinases, cytokines, chemokines, nitric oxide, and reactive
oxygen species (Gorgoulis et al., 2019). Intriguingly, these findings
suggest that the senescent/dystrophic microglia, and not the hy-
pertrophic microglia, could produce the chronic inflammatory
mediators associated with neuroinflammation and inflammaging.
Even a small number of senescent cells in any organ can contribute
to disease and by the spread of the senescence phenotype to
neighboring healthy cells (Hoare and Narita, 2013).
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The hypothesis that dystrophic microglia is an age-associated
microglia morphology has not been experimentally tested. While
cellular senescence generally increases with age, it can occur at
any stage of life in response to stressors (Gorgoulis et al., 2019).
This led our first question: are dystrophic microglia associated
with chronological age in people? We hypothesized that with
increasing years, there would be an increasing proportion of
dystrophic microglia. Previous work, including our own, has found
dystrophic microglia in aged humans without neurodegenerative
pathology (Bachstetter et al., 2015; Lopes et al., 2008; Streit et al.,
2004).
In contrast to the view that dystrophic microglia are purely an
age-related change in microglial morphology, there is compelling
evidence that dystrophic microglia aremore closely associated with
neurodegenerative disease. Previous studies identified dystrophic
microglia in people with age-related neurodegenerative disease,
including Alzheimer's disease (AD) (Bachstetter et al., 2015; Lopes
et al., 2008; Sanchez-Mejias et al., 2016; Streit et al., 2009;
Tischer et al., 2016), Down syndrome (Streit et al., 2009; Xue and
Streit, 2011), Huntington disease (Simmons et al., 2007), dementia
with Lewy bodies (Bachstetter et al., 2015; Streit and Xue, 2016),
limbic-predominant age-related TDP-43 encephalopathy (LATE)
(Bachstetter et al., 2015), and multiple sclerosis (Hametner et al.,
2013). These findings lead to our second question: is increased
dystrophic microglia a disease associated phenomenon? We hy-
pothesized that the absolute numbers, and/or percentage of
dystrophic microglia, would be greater in people with neurode-
generative disease than age-matched controls.
To address these questions, we studied brains from the Uni-
versity of Kentucky Department of Pathology and the UK-ADRC
biobank, covering the adult lifespan from 10e90þ years of age.
Stereological counts of the total number of microglia, number of
hypertrophic microglia, and the number of dystrophic microglia
were conducted in 3 brain regions: hippocampal CA1, frontal
cortex, gray matter, and white matter. We found that in the
absence of neurodegenerative disease, there was only a modest
increase in dystrophic microglia with age. However, with neuro-
degenerative pathology, the percentage of microglia observed to
be dystrophic was much greater than aged-matched controls.
Previous studies have suggested dysfunctional iron metabolism
could lead to increased oxidative stress contributing to the
degeneration of microglia (Streit et al., 2020). In brains with
neurodegenerative pathology, we found a strong association of
ferritin light chain (FTL), a protein responsible for storing intra-
cellular iron, with dystrophic microglia compared with other
microglia morphologies.
2. Materials and methods
2.1. Human subjects
Tissue samples that contained the hippocampus or frontal cor-
tex were acquired from the University of Kentucky biobank and
from the University of Kentucky Department of Pathology and
Laboratory Medicine. The reason for using these latter cases was to
incorporate data from younger patients. Cases were selected by the
investigators (JHN and PTN), with the exclusion criteria of patho-
logically confirmed neurodegenerative disease: specifically, but not
limited to, advanced disease pathology associated with AD neuro-
pathologic change (NC), Lewy body pathology, LATE NC (LATE-NC),
and vascular dementia. Demographic data are presented in Table 1.
The matching hippocampus and frontal cortex were not available
for all cases. Three additional cases of LATE-NC, not part of the
original cohort were used for the IBA1/FTL analysis.
2.2. Immunostaining
Immunohistochemical staining for IBA1 was completed as pre-
viously described (Bachstetter et al., 2015). Briefly, microwave an-
tigen retrieval (6 minutes (power 8, 500 Watts) using citrate buffer
(Declare buffer, Cell Marque; Rocklin, CA) was performed after
deparaffinization on 8 mm-thick tissue sections. Endogenous per-
oxidases were quenched in 3% H2O2 in methanol for 30 minutes.
The sections were blocked in 5% normal goat serum at room tem-
perature for 1 hour. The sections were incubated in primary anti-
bodies IBA1 (rabbit polyclonal, 1:1,000, Wako Catalog no. 019-
19741, AB_839504); 20e24 hours at 4 C. A biotinylated secondary
antibody (Vector Laboratories 1:200) was amplified using avidin-
biotin substrate (ABC solution, Vector Laboratories, catalog no.
PK-6100), followed by color development in NovaRed or DAB
(Vector Laboratories). The double-label immunofluorescence was
completed as previously described (Gal et al., 2018). Briefly, mi-
crowave antigen retrieval (6 minutes (power 8, 500 Watts) using
citrate buffer (Declare buffer, Cell Marque; Rocklin, CA) was carried
out after deparaffinization on 8 mm-thick tissue sections. The sec-
tions were incubated for 45 seconds at room temperature in a 1x
solution of TrueBlack (Cat. #23007, Biotium, Fremont, CA) prepared
in 70% ethanol, to reduce autofluorescence. After blocking in 5%
normal goat serum, the sections were incubated in IBA1 (rabbit
polyclonal, 1:1,000, Wako Catalog no. 019-19741, AB_839504) and
ferritin light chain (mouse clone D9, 1:100, Santa Cruz, Catalog no
sc-74513, AB_1122837) for 20e24 hours at 4 C. The sections were
incubated in secondary antibodies conjugated to Alexa Fluor probes
(Life Technologies, 1:200) at room temperature for 1 hour. Control
sections were included for each case that omitted one or both of the
primary antibodies.
2.3. Quantitative image analysis
Briefly, the Zeiss Axio Scan Z.1 digital slidescanner was used to
image the entire stained slide at 40xmagnification to create a single
high-resolution digital image. Halo software (version 2.3; Indica
labs) was used to view the images. After the fractionator method of
stereology, we used the Halo software to generate counting frames
250 x 250 mm, with a 150 mm gap between counting frames using
Table 1
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systematic random sampling. A total of 10e20 counting frames
were quantified to estimate the number of microglia per unit area
in the three brain regions. Classification of microglia as either hy-
pertrophic or dystrophic followed our previously described criteria
(Bachstetter et al., 2015). Example photomicrographs of represen-
tative cells defined as either hypertrophic or dystrophic microglia is
shown in Fig. 1. The results were confirmed by 2 independent ob-
servers (REH and NGC) blind to experimental conditions. Data
presented are from REH's quantification. Numbers of dystrophic
microglia in cases with neurodegenerative disease were generated
as part of our prior published study (Bachstetter et al., 2015), and
follow comparable methods to those described previously.
For the IBA1 and FTL colocalization analysis, a Zeiss Axio Scan Z.1
digital slidescanner was used to image the entire stained slide at
40x magnification to create a single high-resolution digital image.
Halo software (version 2.3; Indica Labs) was used to view the im-
ages. Using HALO imaging software and viewing only the IBA1
channel when counting and determining the morphology of the
cells, we generated an region of interest around each microglia and
define it as ramified, hypertrophic, or dystrophic. We identified at
random 10 microglia from each morphology for each of 3 cases of
LATE-NC. We then used the area colocalization FL algorithm (Halo
software, version 2.3; Indica Labs) on the region of interests to
determine the area of colocalization of IBA1 and FTL for the 3
microglia morphologies.
2.4. Statistics
JMP Pro software version 14.0 (SAS institute, Cary, NC, USA) or
GraphPad Prism software version 8.0 was used to generate graphs
and for statistical analysis. Linear regression and Spearman r were
used to compare the effect of age on microglia morphological state.
Mean  95% confidence interval are shown for the regressions, as
well the data point for each case. The standard least squares model
used to compare hypertrophic and dystrophic microglia was cor-
rected for age. Source data are available in supplemental Tables 1e3
3. Results
Microglia can be classified into distinct morphologies using IBA1
immunohistochemistry. As previously described (Bachstetter et al.,
2015), the morphologies include ramified microglia, which are
thought to be a healthy or homeostatic morphology (Fig 1A, B). In
contrast, the hypertrophic microglia morphology has historically
been associated with a reactive microglia response. This
morphology is typically observed after acute neuronal injury and
surrounding amyloid plaques (Fig 1C, D). As previously described,
dystrophic microglia morphology refers to a number of morpho-
logical changes affecting the cytoplasmic processes such as sphe-
roidal swelling, deramified, beaded, discontinuous, or tortuous
processes (Fig 1E, F) (Streit et al., 2004). A trained scientist can
quantify these 3 distinct microglia morphologies. Thus far, we have
been unsuccessful in training computer algorithms, including
neural network algorithms, in detecting these morphologies accu-
rately. Therefore, we adopted a design-based stereological
approach and replicated the quantification using 2 observers’ blind
to the experimental conditions (R.E.H and N.G.C).
3.1. Age affects microglial morphology in hippocampal subregions
of the human brain
To better understand the link between dystrophic microglia and
age, we began examining the CA1 region of the hippocampus.
Regardless of microglia morphology, we found a strong correlation
for an increase in the number of microglia with greater age (Fig 2A).
Similarly, we also observed a rise in the number of hypertrophic
Fig. 1. Representative examples of the microglia morphologic appearances seen in the cases. (A, B) show examples of the ramified microglia. Hypertrophic microglia are shown in
(C, D). In (C), microglia can be seen surrounding the soma of a pyramidal neuron. (E) shows dystrophic microglia with swellings, beaded, and discontinuous processes. (F) shows an
example of dystrophic microglia that are small and deramified, with beaded processes. The scale bar is 50 mm.
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microglia (Fig 2B) and dystrophic microglia (Fig 2C) with age. We
next tested if there was a change in the proportion of microglia that
were hypertrophic or dystrophic as a function of age.We found that
when the hypertrophic microglia were compared as a percentage of
the total microglia, there was a strong positive correlation for an
increased percentage of hypertrophic microglia with age (Fig 2D).
We did not find evidence in support of our hypothesis that dystro-
phic microglia were associated with age, as there was a lack of a
correlation for the percentage of dystrophic microglia to total
microglia with age (Fig 2E). That is, while the total number of
dystrophic microglia increases with age in the CA1 region of the
hippocampus (Fig 2C), this change can be accounted for by the age-
related increase in the total number ofmicroglia (Fig 2A). The lack of
an associationwith age and dystrophicmicroglia is in contrast to the
hypertrophic microglia, which are increasing with age (Fig 2D).
3.2. Changes in microglial morphology in neocortical gray matter
regions of the brain
Next, we evaluated changes in the spatial distribution of
dystrophic microglia in the neocortical gray matter of the frontal
cortex. Investigation of microglia in frontal lobe gray matter
demonstrated several striking differences in comparison with the
hippocampus. While the total number of microglia was found to
increase with age (Fig 3A), there was no age-related increase in the
number of hypertrophic microglia in the frontal cortex (Fig 3B).
Counts of the number of dystrophic microglia were correlated with
age (Fig 3C). As a proportion of the total microglia, hypertrophic
microglia did not increase with age (Fig 3D), while there was an
increase in the percentage of dystrophic microglia with age (Fig 3E).
3.3. Changes in microglial morphology in white matter regions of
the brain
In addition to the limbic and neocortical gray matter, we also
quantified microglia in the white matter of the frontal cortex. We
found that the total number of microglia (Fig 4A), the number of
hypertrophic microglia (Fig 4B), and the number of dystrophic
microglia (Fig 4C) did not increase with age in the white matter. In
addition, the percentage of hypertrophic microglia (Fig 4D) or
dystrophic cells (Fig 4E) was unchanged with age.
3.4. Dystrophic microglia are a disease-associated microglia
morphology
Given that we found no evidence of dystrophic microglia
increasing with age in the hippocampal CA1, we next asked if
dystrophic microglia could be characteristic of a disease-associated
microglia morphology. To address this hypothesis, we compared
changes in dystrophic microglia in the hippocampal CA1 region
from people who were greater than 65þ years old without neuro-
degenerative pathology, to 65þ years old people with either AD
neuropathological change, LATE-NC, or Lewy body pathology from
a pre-existing data set (Bachstetter et al., 2015) (Table 2). Our results
were contrary to common assumptions. In the hippocampal CA1
region, people with neurodegenerative pathology had the same or
fewer hypertrophic microglia compared with age-matched controls
(Fig 5A). These results are in contrast to what was found for
dystrophic microglia. In the cases with neurodegenerative pathol-
ogy, on average, 45% of the microglia were found to be dystrophic.
This is in comparison with the cases without neurodegenerative
pathology, where on average, only 9% of the microglia were
dystrophic (Fig 5B). While the range of dystrophic microglia were
broad (0%e100%) for the people in the neurodegenerative group
level, there was no statistical difference between the different
neurodegenerative disease. These results suggest that the dystro-
phic microglia represent a disease-associated microglia
morphology.
3.5. Iron metabolism as a molecular mechanism for the dystrophic
diseaseeassociated microglia morphology
Single-cell and single-nuclei transcriptomic approaches have
defined a gene signature in microglia associated with
Fig. 2. Effect of age on microglial morphology in the CA1 region of the hippocampus. (A) The total number of microglia, regardless of morphology, was found to increase with age in
the hippocampus. The total number of hypertrophic (B), as well as dystrophic microglia (C), was also found to increase in the hippocampus with age. The percentage of the total
microglia which are hypertrophic was found to increase with age (D), while the increase in percentage of microglia that were dystrophic (E) was proportional to the total number of
microglia, and thus did not increase with age. Each circle is a unique person.
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neurodegenerative pathology (Butovsky et al., 2014; Galatro et al.,
2017; Keren-Shaul et al., 2017; Mathys et al., 2019; Orre et al.,
2014). Exploring these data sets, we identified genes associated
with the iron homeostasis enriched in aging and disease-
associated microglia. While several gene members of the iron
homeostatic pathway were differentially expressed in the aging
and disease-associated microglia, FTL was one of the iron pathway
genes found to be increased across multiple data sets. In addition,
prior studies have observed dystrophic microglia labeled by FTL
(Hametner et al., 2013; Lopes et al., 2008). Therefore, we next
hypothesized that dystrophic microglia in the aged brain with
neurodegenerative disease pathology would be FTL positive. To
test this, we used 3 LATE-NC cases and double labeled those cases
using IBA1 and FTL (Fig 6A). Using the IBA1 channel alone, we
identified 10 ramified microglia, 10 hypertrophic microglia, and 10
dystrophic microglia per case. Using HALO imaging software, we
determined the area of colocalization of IBA1 and FTL for each
microglia (Fig 6B). In support of our approach, we found that the
intensity of the IBA1 staining in the cells classified as hypertrophic
was greater than the cells classified as ramified or dystrophic
Fig. 3. Stereological quantification of microglia morphology in the frontal cortex gray matter as a function of age. (A) The total number of microglia was found to increase with age.
(B) However, hypertrophic microglia showed no age-related increase. (C) Dystrophic microglia were found to increase with age. (D) The percentage of total microglia that were
hypertrophic did not increase with age; whereas, (E) dystrophic did increase with age in the frontal cortex gray matter. Each circle is a unique person.
Fig. 4. Effect of age on microglial morphology in the frontal cortex white matter. The number of total microglia (A), as well as the number of hypertrophic (B) and dystrophic (C)
microglia did not increase in the white matter of the frontal cortex. Similarly, there was no change in the percentage of hypertrophic (D) or dystrophic microglia (E).
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microglia (Fig 6C; p < 0.0001 Tukey's test). We then asked, do the
cells we defined as dystrophic have greater amounts of FTL.
Comparing the area of IBA1þFTLþ colocalization, we found that
the dystrophic microglia had much more FTL as a proportion of
the overall cell than the ramified or hypertrophic microglia (Fig 6D
p < 0.0001 Tukey's test).
4. Discussion
In the nearly 2 decades since dystrophic microglia were first
described (Streit et al., 2004), the causes and consequences of this
unique cellular morphology remains undefined (for review see
(Streit et al., 2020)). Such as other types of cellular senescence that
occur with age, we asked if aging was sufficient to drive microglia
toward a dystrophic microglia morphology in the absence of dis-
ease. To begin to address these critical knowledge gaps, we used a
series of autopsy cases covering the human lifespan to define the
association of dystrophic microglia with age. We found only limited
evidence that dystrophic microglia increased with age in the
absence of neurodegenerative pathology. We saw in the hippo-
campal CA1 region, a robust age-related increase in the total
number of microglia, as well as the total number of hypertrophic
and dystrophic microglia. However, as a percentage of the total
number of microglia, only the hypertrophic microglia morphology
was found to increase with age. At the same time, there was no
relationship between age and the percentage of dystrophic micro-
glia. In the gray matter of the neocortex, a modest increase in the
percentage of dystrophic microglia was seen with age, suggesting a
possible regional vulnerability in the presence of dystrophic
microglia, which will warrant future studies. After observing a
general lack of an associationwith age and dystrophic microglia, we
next asked if dystrophicmicroglia are a disease associatedmicroglia
morphology. In contrast to the aged brain without neurodegener-
ative disease, we found strong evidence that dystrophic microglia
are a disease-associatedmicroglia morphology.While there is likely
more than one mechanism that push microglia into a dystrophic
morphology, we identified iron metabolism as a potential molec-
ular mechanism warranting future study.
We used a two-dimensional stereological approach to quantify
the number of microglia by their morphologic appearance. In the
scarce tissue samples used in our study, it was not feasible to use
three-dimensional stereological approaches, such as the optical
fractionator, which would account for changes with tissue
shrinkage caused by fixation (Gundersen et al., 1988; Sterio, 1984).
There is also subjectivity associated with our methods as the
observersdwhowere blind to the experimental groupsdneeded to
classify a cell as hypertrophic, dystrophic, or other. We used a
number of approaches to limit the subjectivity. For example, we
repeated the assay using 2 independent scientists. We also tested
intraobserver variability by having the same scientist replicate a
subset of their microglia counts. Our results are comparable with
those of Davies et al., which used morphometric approaches to
quantify microglia arborization and microglia coverage and found a
decrease in microglia complexity and area of the brain covered by
microglia in the AD brain compared with the matching control
brains (Davies et al., 2017). In addition, an age-related decrease in
the microglia markers CD68 and major histocompatibility complex
class II were seen in AD brains, whereas there was no change in the
control cases with age (Hoozemans et al., 2011), which is in
agreement with our results. While we acknowledge the limitations
associated with our approach, our study provides a quantitative
assessment of microglia number by morphology across the human
lifespan, which has not been previously reported.
Our results that dystrophic microglia are the dominant disease-
associated microglia morphology may appear counter to the cur-
rent assumptions that neurodegenerative disease is associated with
microglia activation. Indeed, as thoroughly reviewed by Hopperton
et al., the vast majority of studies do find that microglia/macro-
phages are increased in AD brains compared with control
(Hopperton et al., 2018). However, the likelihood that the study will
report an increase in microglia/macrophages AD brains compared
with control is greater when activation marker (e.g., IL-1a) or a
marker of macrophages (e.g., CD163) is used (Hopperton et al.,
2018). Our results are not in disagreement with these findings.
We hypothesize that there may be a loss of homeostatic microglia
in the neurodegenerative disease brain, with a compensatory in-
crease in monocytes/macrophages.
We did find with age in the present study and with neurode-
generative disease in our previous study (Bachstetter et al., 2015)
the total number of IBA1þ cells in the CA1 region of the hippo-
campus was increased in the brain with neurodegenerative pa-
thology compared with the control brains. The increase in total
number of microglia/macrophages may be compensatory for the
loss of homeostatic coverage of the brain parenchyma by microglia.
Studies using depletion approaches to eliminate microglia in ani-
mal models have clearly shown that the brain will quickly repo-
pulate microglia to maintain a tiling of microglia across the brain
(Najafi et al., 2018). However, the rate of repopulation slows after
multiple rounds of depletion (Najafi et al., 2018).
Comparative studies of dystrophic microglia provide important
insights into the biology of this cellular morphology. In marmosets,
it was found that the number of dystrophic microglia increased
with age in both the limbic cortex and neocortex. However, they
found this increase peaked in late middle age marmosets and de-
clines in the oldest aged marmosets (Rodriguez-Callejas et al.,
2019). These results are in contrast to our present study, where
we saw the total number of dystrophic microglia increase linearly
Table 2
Neurodegenerative series characteristics
Experimental group Number of cases Sex Age range
Female Male
Healthy control 34 16 13 65e93
AD-NC 8 3 5 65e85
LBP 11 2 9 65e97
LATE-NC 9 5 4 65e93
Fig. 5. Association of dystrophic microglia with neurodegenerative disease. Comparing
the percentage of hypertrophic and dystrophic microglia in the CA1 region in the 65þ-
year-old cases free of advanced neurodegenerative disease pathology (negative) to
those cases with advanced stage neurodegenerative disease pathology (positive) (A)
showed a decrease in the number hypertrophic microglia (p ¼ 0.0998), and a (B)
significant increase in dystrophic microglia (p ¼ 0.00002) in the cases with advanced
stage neurodegenerative disease. Open symbols are from cases from the present study.
Closed symbols are from our prior study (Bachstetter et al., 2015). Alzheimer's disease
neuropathologic change, Lewy body pathology (LBP), LATE neuropathologic change
(LATE-NC).
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with age. In aged chimpanzees, dystrophic microglia were found
primarily in the neocortical gray matter of layer IIeIII (Edler et al.,
2018). While amyloid and tau neuropathologic changes were
found in a subset of the aged chimpanzees used in the study,
quantification of dystrophic microglia was not completed, so it re-
mains to be determined if there is an association between dystro-
phic microglia and amyloid and tau in the chimpanzees (Edler et al.,
2018). In Cynomolgus macaques exposed to chronic manganese to
model Parkinson's diseaseerelated pathology, dystrophic microglia
were found to have intracellular ferric iron (Verina et al., 2011),
which is in agreement with our findings that FTL is highly
expressed in dystrophic microglia. In addition, in tree shrews
(Tupaia belangeri), dystrophic microglia have been shown to in-
crease with age (Rodriguez-Callejas et al., 2020). Interestingly,
ferritin-labeled microglia was high in oxidative stress markers and
had internalized hyperphosphorylated tau (Rodriguez-Callejas et
al., 2020). In mice, dystrophic microglia are seldom reported;
however, a recent study did find in a mouse model of P301S tau-
opathy, a decrease in microglia complexity in the tau mouse with
age, which could be contributed to a dystrophic microglia
morphology (van Olst et al., 2020).
Studies of dystrophic microglia and their role in disease are faced
with several limiting factors that have slowed progress in the field.
One of the most prominent limitations is the lack of distinct cell
Fig. 6. Dystrophic microglia have a strong tendency to be double labeled for FTL in the hippocampus of aged humans with LATE-NC. A quantitative cellular localization of FTL found
colocalization FTL with microglia. FTL did not appear to be staining all microglia; therefore, we sought to see if there was any association of FTL with the different microglia
morphologies we recently characterized. (A) Shows an example of the IBA1þFTLþ staining. (B) Shows the HALO-generated markup, where green is IBA1, red is FTL, and yellow is the
area where the 2 proteins are colocalized. (C) Shows that there was greater IBA1 staining intensity in the hypertrophic microglia than the 2 different morphologies for the IBA1
markup area (p < 0.0001, Tukey Test). (D) A high degree of IBA1þFTLþ area of colocalization in the dystrophic microglia compared with the ramified or hypertrophic morphologies
(p < 0.0001, Tukey test). Circles are individual microglia, from 3 different aged brains. The scale bar is 20 mm. (For interpretation of the references to color in this figure legend, the
reader is referred to the Web version of this article.)
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markers delineating dystrophic microglia. For this reason, future
studies must attempt to find novel cellular markers of dystrophic
microglia, as well as identifying specific changes in cells that
contribute to disease progression. Our study was not the first to
identify FTL as a marker enriched in dystrophic microglia. Previous
studies have reported that microglia increase FTL in neurodegener-
ative disease (Hopperton et al., 2018; Streit et al., 2020). However, our
work, along with Lopes et al. (Lopes et al., 2008), has demonstrated
that the increase in FTL may be more than a marker of a reactive
microglia morphology and could suggest a mechanism in iron dys-
homeostasis that is leading to the degeneration of microglia. Single-
nuclei and single-cell data sets support the hypothesis that iron
pathway is differentially expressed in disease-associated microglia
(Galatro et al., 2017; Keren-Shaul et al., 2017;Mathys et al., 2019; Orre
et al., 2014). Our quantitative methods to measure FTL in LATE-NC
cases found that a greater amount of the dystrophic microglia was
labeled with FTL in comparison with hypertrophic microglia. Recent
work in aged marmosets found that FTL labeled both activated and
dystrophic microglia morphology (Rodriguez-Callejas et al., 2019).
These findings are consistent with our work as we too can identify
FTL labeled hypertrophic microglia. We propose that these hyper-
trophicmicroglia could represent a point of inflection in the course of
disease pathology, whenmicroglia lose their ability to safelymaintain
iron homeostasis and become dystrophic. Alternatively, we previ-
ously showed that FTL was found to be colocalized with TDP-43 and
tau inclusion bodies (Gal et al., 2018). The increase in FTL could be
part of a proteinopathydincluding TDP-43 and taudleading to the
degeneration of microglia and neuronal cells. More work is needed to
directly measure iron burden in FTL positive microglia from brains
with and without neurodegenerative pathology. For instance, Fe(II)
and Fe(III) could be measured on fluorescence-activated cell sorting
sorted microglia from the postmortem tissue using capillary elec-
trophoresis coupled to inductivelyecoupled plasma mass spectrom-
etry (Michalke et al., 2019).
Recent studies have shown alterations in microglial morphology
in the cortical white matter of patients with neurodegeneration
related to age (Hopperton et al., 2018). However, the relation be-
tween dystrophic microglia and white matter degradation is still
unknown. It has traditionally been held that morphologic changes
in white matter microglia are related to neuroinflammation char-
acterized by an increased expression of major histocompatibility
complex class II and complement receptor C3bi (Hopperton et al.,
2018). Conversely, more recent studies posit that the breakdown
of myelin associated with age places an increased burden on white
matter microglia and that observed increases may be related to cell
senescence rather than inflammation (Streit et al., 2020). In our
experiments, we did not find any changes in microglia morphology
in the white matter of frontal cortex associated with healthy aging.
Future studies are needed to define the link between genetic
predispositions and specific changes to glial microenvironment and
function, to uncover the role of dystrophic microglia in other pro-
gressive neurodegenerative diseases. The presence of dystrophic
microglia in diseases with varying etiology and pathology suggests
that dystrophic microglia are critically involved in the shift from
normal aging to disease states. Dystrophic microglia have decreased
neuroprotective abilities and increased secretion of proin-
flammatory molecules (Streit et al., 2020). To date, the role that
dystrophic microglia play in normal aging and neurodegeneration
is still unknown. However, based on our findings, a loss of microglia
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